Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Fig. 4

Establishment of a humanized Ph+ALL xenotransplant model using anti-CD122-conditioned NOD/SCID mice and intra-bone marrow injection (IBMI) with LPCs from Ph+ALL patients. a Compared with an irradiated non-transplanted control mouse (Ctrl), the mouse transplanted with LPCs and treated with vehicle (Vehicle) exhibited significant splenomegaly at 12 weeks post-transplant. A low-magnification image of human Ph+ALL engraftment in a bone section (left panel), May-Giemsa staining (middle panel) and fluorescence in situ hybridization (FISH) analysis (right panel) of leukemic blasts in the BM of the recipients (Vehicle). b Flow cytometric analysis demonstrated that the BMs of the recipients were efficiently engrafted with human Ph+ALL cells with an aberrant phenotype similar to that in the donor Ph+ALL patients. c Human engraftment of the BM, spleen, liver and kidney of the recipient (Vehicle) was further confirmed by HE staining (upper panels) and IHC with anti-hCD19 antibody (lower panels)

Back to article page